Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,602

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Post-mastectomy Pain SyndromeBreast CancerPain, PostoperativePain, Chronic
Interventions
DRUG

Lidocaine 20mg/ml

Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).

DRUG

Placebo

Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).

Trial Locations (16)

Unknown

RECRUITING

Foothills Medical Centre, Calgary

RECRUITING

Sturgeon Community Hospital, Edmonton

RECRUITING

Eastern Health- Health Sciences Centre, St. John's

RECRUITING

IWK, Halifax

RECRUITING

Juravinski Hospital, Hamilton

RECRUITING

North York General Hospital, North York

RECRUITING

The Ottawa Hospital, Ottawa

RECRUITING

Thunder Bay Regional Health Sciences Centre, Thunder Bay

RECRUITING

Humber River Hospital, Toronto

RECRUITING

Mount Sinai Hospital, Toronto

RECRUITING

St. Michael's Hospital, Toronto

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

RECRUITING

University Health Network, Toronto

RECRUITING

Women's College Hospital, Toronto

RECRUITING

Hôpital Maisonneuve-Rosemont, Montreal

RECRUITING

Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University Health Network, Toronto

OTHER